Phase II clinical study of RG3502 in HER2 positive breast cancer patients

Phase II clinical study of RG3502 in HER2 positive patients with locally advanced/recurrent or metastatic breast cancer

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221240

Enrollment

Registered

2010-09-13

Start date

2010-09-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2 positive Breast Cancer

Interventions

investigational material(s) Generic name etc : RG3502 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material :

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: - Inoperable, locally advanced/recurrent or metastatic breast cancer - HER2-positive (FISH + or IHC 3+) - ECOG PS :0-2

Exclusion criteria

Exclusion criteria: - Clinically significant cardiac disease - Grade 3 or higher Hypersensitivity to trastuzumab

Design outcomes

Primary

Measure	Time frame
Response rate based on Efficacy Review Committee assessment RECIST ver. 1.1	—

Secondary

Measure	Time frame
Efficacy, Safety, Pharmacokinetics, Anti-RG3502 antibodies RECIST ver. 1.1, CTCAE ver. 4.0	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026